Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.

Forty patients with advanced breast cancer, randomised to receive CMF or weekly low dose Epirubicin, were evaluated by UICC criteria of response and WHO toxicity criteria, in addition to three QoL instruments: the 'Qualitator' daily diary card, 4 weekly Nottingham Health Profile (NHP) and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fraser, S. C., Dobbs, H. J., Ebbs, S. R., Fallowfield, L. J., Bates, T., Baum, M.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1993
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1968186/
https://ncbi.nlm.nih.gov/pubmed/8431375
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados